TokenPost·
Merck and Moderna Report 42% Relative Risk Reduction in Melanoma Trial
4 outlets reporting
42%
risk reduction
The iShares Biotechnology ETF (IBB) had a year-to-date NAV total return of 25.41% as of Oct. 21.
Also covered by 3 outlets
More news
- TokenPostStrategy Raises Preferred-Share Repurchase Authorization to $3 Billion
- TokenPostPost Claims OpenAI Offered Discounts as It Competes With Anthropic
- TokenPostAlgorand Adds Rekeying for Falcon-1024 on Existing Accounts
- Crypto BriefingApollo economist warns AI boom may be unsustainable as stocks tumble
- TokenPostS&P 500 Firms Beat EPS Estimates at an 82% Rate in Weekly Tally
- TokenPostU.S. Real Estate Gauges Gain 0.86% as Earnings Move Shares